The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to transition back into research on next-generation mRNA therapeutics.

The administration had cut crucial funding for mRNA-based therapies. The rest of the world might step in and benefit.

A group of experts that advises the US Centers for Disease Control and Prevention on its vaccine recommendations has suspended an anticipated push to stop recommending mRNA-based Covid-19 vaccines ...

Health and Human Services Secretary Robert F. Kennedy Jr. revealed his agency will be cutting funding to mRNA development, calling the vaccine technology "ineffective" and claiming it poses more risks ...

If licensed and in the event of an influenza pandemic, Moderna will allocate 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable ...

The leadership changes arrive as BioNTech reported a 57% rise in net losses for 2025.

CAMBRIDGE, MA / ACCESS Newswire / December 15, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...

In early February 2026, the U.S. District Court for the District of Delaware denied Moderna’s bid for summary judgment in a multi-billion-dollar patent infringement case brought by Arbutus Biopharma ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.